Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Post-poned boost mRNA-Erasmus Medical Center-COVID-19
- Development stage
- Unknown
- Lead developer
- Erasmus MC
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Post-poned boost mRNA-Erasmus Medical Center-COVID-19 refers to a specific intervention arm within the **SWITCH ON** clinical trial (NCT05471440), a multicenter, randomized, controlled study led by the **Erasmus Medical Center**. This intervention involves the administration of a bivalent mRNA-based COVID-19 booster vaccine (typically the Omicron-adapted formulations from Pfizer-BioNTech or Moderna) to healthcare workers. The "post-poned" strategy specifically evaluates the immunogenicity and clinical efficacy of delaying an additional booster dose compared to immediate administration ("direct boost"). The study aims to address public health policy questions regarding the necessity and timing of repeated booster vaccinations in healthy populations with high existing immunity from primary series and prior boosters. The vaccine works by delivering mRNA encoding the SARS-CoV-2 spike protein, inducing both humoral and cellular immune responses against the virus.
- Other names
- Post-poned boost mRNASWITCH ON trial mRNA arm
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on Post-poned boost mRNA-Erasmus Medical Center-COVID-19.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Post-poned boost mRNA-Erasmus Medical Center-COVID-19.